Wird diese Nachricht nicht richtig dargestellt, klicken Sie bitte hier.
Deutsche Sarkom Stiftung
• SPAGN Member groups • Unsubscribe newsletter • Contact
Dear SPAGN Members and Friends,

As we all know sarcoma's patient journey is unique for every individual, and we encourage patients to share their stories to inspire and support one another. Take a sneak peak into Natalia's story below. 👀

Additionaly, there's always a lot happening in the sarcoma world, which is why it we’re excited to be attending the ESMO Sarcoma & Rare Cancers conference where we’ll be sharing the first results from the Diagnosis Pathway Survey. Besides the interesting findings from the survey, SPAGN will be represented by a booth and will be taking part in one more session.

Be sure to stop read below and stop by if you are attending ESMO in Lugano!🖐

💊 Last but not least, read more on new trial results and FDA approvals that could change the landscape for sarcoma treatments.

All the best from the
SPAGN Board of Directors & Team
📝 Chek Out Our New Blog Post: Metaphors That Matter 

Our latest blog features Natalia, who shares how metaphors help her navigate the challenges of living with sarcoma. Her story is a heartfelt reflection on resilience, community, and finding meaning in difficult times.
SPAGN's Involvement: ESMO Sarcoma and Rare Cancers 2025!
We are so excited for the upcoming ESMO Sarcoma & Rare Cancers conference 2025! Once again, SPAGN will have a booth, so be sure to stop by and connect with us.
 
We are also thrilled to be presenting the first data from the SPAGN Diagnosis Pathway Survey during our session, Making an Impact on Patient Outcomes, on Thursday, March 20, from 14:15 to 15:45 in Hall E.
 
Also, our board members, Roger and Gerard, will also be part of the Listening to Patients session on Thursday, March 20, from 10:30 to 12:00 in Hall E.
 
We can’t wait to see you there and engage in meaningful discussions!
📜 DEFİ Trial Plain Language Paper Is Now Published
The Plain Language Summary of the DeFi Study, examining if the drug called nirogacestat (Ogsiveo®) could slow disease progression and improve disease symptoms. The study included 142 adults with progressing desmoid tumors.
 
The study found that Nirogacestat reduced the chance of a participant’s disease getting worse during the study by 71% compared with a placebo. Also 41% of the participants had their tumors respond to treatment with nirogacestat. 7% of the participants had their tumors disappear completely and 34% of the participants had their tumors shrink by at least 30% during the study.

The study results offer promising insights into potential treatments for this challenging condition. 
💊 Exiting news: FDA Approved Vimseltinib for TGCT

Big news in the sarcoma world: The FDA has approved vimseltinib for the treatment of symptomatic tenosynovial giant cell tumor (TGCT). This approval marks an important step forward in providing better treatment options for patients affected by this rare condition.
 
Follow us on our Whatsapp Channel! Join here!
 
X handle Facebook Company Name Instagram Profile YouTube channel LinkedIn company page
Sarcoma Patient Advocacy Global Network e.V./Assoc., 
Untergasse 36,
61200 Wölfersheim/Germany
Wenn Sie diese E-Mail (an: unknown@noemail.com) nicht mehr empfangen möchten, können Sie diese hier kostenlos abbestellen.